Ankylosing spondylitis in Senegal: epidemiological, diagnostic, therapeutic and evolutionary features at the Hospital Center University Aristide Le Dantec, Dakar

• Published in: The Pan African medical journal Vol. 40; p. 15
• Main Authors: Abba, Abbasse, Niasse, Moustapha, Diaby, Ladji Mohamed, Ali, Hassan
• Format: Journal Article
• Language: French
• Published: Uganda 2021
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents - therapeutic use; Biological Therapy - methods; Cross-Sectional Studies; Disease Progression; Female; Humans; Male; Methotrexate - therapeutic use; Middle Aged; Prospective Studies; Quality of Life; Retrospective Studies; Senegal; Spondylitis, Ankylosing - epidemiology; Spondylitis, Ankylosing - physiopathology; Spondylitis, Ankylosing - therapy; Young Adult; Senegal; HLA B27; biotherapy; clinical; female predominance; Senegal; evolution; Ankylosing spondylitis
• ISSN: 1937-8688
• DOI: 10.11604/pamj.2021.40.15.29525

ankylosing spondylitis (AS) is a progressive disease, which can result in disability. The purpose of this study is to describe the epidemiological, diagnostic, therapeutic and evolutionary features of AS in the Department of Rheumatology of the Hospital Center University Aristide Le Dantec, Dakar. we conducted a descriptive and analytical cross-sectional study. Data were collected on a prospective and retrospective basis over a period of 8 years, between January 2012 and December 2020. Patients were diagnosed with AS on the basis of ESSG (European Seronegative Spondylarthropathy Group) and Amor diagnostic criteria, ASAS (Assessment of Spondyloarthritis International Society) criteria and modified New York criteria. Data were collected by a structured questionnaire and analyzed using the SPSS25 (Statistical Package for the Social Sciences) software. six hundred forty-seven patients met the inclusion criteria (414 women and 233 men) with a sex ratio of 1.77F/1M. Different symptomatic cases were found: axial disease (55.65%), mixed disease (44.35%) and systemic disease with extra-articular manifestations including uveitis (12.21%), aortic insufficiency (5.71%) and fibrobullous lung disease (3.86%). Sixty percent of patients were receiving non-steroidal anti-inflammatory drugs (NSAIDs), 47% methotrexate, and 0.92% biotherapy. Disease activity index, functional index and quality of life index enabled disease monitoring. our results show that there was predominance in women. Patients were mostly affected by axial spondyloarthritis. More than half of our patients were treated with anti-inflammatory, 47% with methotrexate and 0.92% with biotherapy. This study highlights that the features of ankylosing spondylitis (AS) are a burden to the patient with spondyloarthritis and disease progression over time.